Research programme: cell cycle checkpoint activators - ArQule

Drug Profile

Research programme: cell cycle checkpoint activators - ArQule

Alternative Names: ARQ-150RP; ARQ-450RP; ARQ-800RP

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator ArQule
  • Class Small molecules
  • Mechanism of Action Checkpoint kinase 2 stimulants; Checkpoint kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 17 Aug 2008 A new series of checkpoint 2 activators presented at the 236th American Chemical Society National Meeting (ACS-2008)
  • 11 Jan 2005 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top